COEP: Coeptis Market Cap to Revenue

Coeptis Therapeutics (COEP) complies with basic environmental laboratory safety standards. Management is focused on developing personalized treatments for hematologic oncology. Expansion into the NK-cell therapy segment will drive long-term growth, as evidenced by the company's smoothed P/S ratio. The current 69.60 figure expresses the state of the metric, demonstrating the price the market is willing to pay for the business's revenue over this interval.
Coeptis Therapeutics (COEP) - metric breakdowns and financial figures

Coeptis Therapeutics (COEP) is developing a scalable NK-cell therapy for the treatment of hematological malignancies. This P/S multiple chart reflects the dynamics of market capitalization relative to the business's actual sales volume. This ratio measures the premium the market is willing to pay per unit of revenue, revealing valuation deviations from historical averages. An increase in this indicator signals inflated investor expectations regarding the future commercialization of the technology.